not used title

not used title

Since the Department of Health and Human Services (HHS) released the Part B International Pricing Index (IPI) model late last year, there have been a number of inaccurate claims floating around about the proposal’s impact on patients, biopharmaceutical innovation and the U.S. health care system. This week, we are setting the record straight on how the proposal, which would set U.S. prices for Part B medicines based on the prices mandated by foreign governments, would most likely result in restricted access for seniors who rely on Part B for their medicines.

Fact: Every time other countries have set prices, it has resulted in restrictions in access to medicines. The recent report from HHS’ Assistant Secretary for Planning and Evaluation (ASPE) found that all 16 countries evaluated in the report had fewer treatment options than in the United States and patients experienced delays in accessing treatment or were denied innovative medicines that could improve their quality of life. This is concerning given U.S. patients currently have, on average, access to 96 percent of new cancer medicines, while patients living in the countries included in the IPI model have access to only half of those medicines, on average. On top of having fewer options, patients in these countries also have to wait years longer, on average, for these medications than patients in the United States. That’s why a broad range of stakeholders have raised concerns with the IPI model’s impact on patient access to medicines.

In addition to research, numerous patient stories shed light on how access restrictions abroad have led to worse health outcomes. A recent Independent article highlights how patients as young as 25 years old are refused a promising multiple sclerosis treatment that can delay the disease and give patients an additional seven years of independence before needing a wheelchair. One U.K. patient shared the harsh reality of this system, explaining “You can’t imagine what it’s like to get a diagnosis and to be told there’s nothing for you.” Its patient stories like these that the Administration must consider before opening the floodgates to flawed foreign pricing policies.

The International Pricing Index Model is the wrong prescription for Medicare and America’s seniors. The Administration must stop the IPI proposal and instead focus on the right prescription for Medicare Part B. Policymakers should pursue changes that fix misaligned incentives, such as those seen in the 340B program, and support the continued shift toward value-driven care. Approaches like these will ensure the Part B program continues to fulfill its promise to seniors. 

Find out more about how the IPI Model is the wrong prescription for Medicare at PrescriptionForMedicare.org.

Nicole Longo

Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Nicole Longo

Author Twitter

Author LinkedIn

What AARP isn’t telling seniors about MFN

August 24, 2026

CMS proposal could discourage patient-centered innovation

August 18, 2026

Nearly 1 in 4 patients initially denied access to IRA medicines

August 6, 2026

Medicare Part D at 20: Building on a strong foundation

July 23, 2026

MFN won’t lower costs when insurers call the shots

May 8, 2026

Guest Blog: How MFN price controls could decide my health care

April 30, 2026

States should avoid repeating the IRA’s price‑setting mistakes 

April 21, 2026

Insurers routinely block seniors’ access to medicines in Medicare Part D

March 18, 2026

MFN undermines U.S. biopharmaceutical innovation

February 25, 2026

CMS puts patients and innovation at risk with MFN

February 24, 2026

New list of selected drugs highlights growing consequences of government price setting

January 28, 2026

Guest blog: Making the most of the Medicare Prescription Payment Plan

December 8, 2025

PhRMA calls on USTR to ensure foreign nations pay their fair share

November 4, 2025

What seniors can expect this open enrollment

October 14, 2025

Part D premiums are going up, while choices are going down

October 8, 2025

Delivering breakthroughs and lower costs for patients

September 8, 2025

Celebrating 60 Years of Medicare

July 30, 2025

Medicare patients face higher drug costs, despite IRA promises

July 22, 2025

Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas

June 16, 2025

New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines

May 21, 2025

Foreign first pricing schemes don’t address why Americans pay more

May 15, 2025

Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change

March 13, 2025

CMS, don’t fall behind the rest of the medical community on obesity

February 14, 2025

A new administration poses new opportunities for patient access

December 17, 2024

Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?

October 18, 2024

Did the administration consider the importance of blood cancer medicines to patients in price setting process?

October 8, 2024

Did the administration consider the importance of blood clot medicines to patients in the price setting process?

September 25, 2024

The Inflation Reduction Act could increase costs and reduce access for millions of seniors

September 17, 2024

Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.

September 16, 2024

Did the administration consider the value of innovative diabetes medicines in price setting process?

August 28, 2024

New survey: Insurers confirm IRA will reduce patient treatment options

August 20, 2024

The unintended consequences of government price setting in Medicare Part D

August 16, 2024

Don’t put the government between patients and their medicines

August 7, 2024

Biosimilars continue to drive market competition and increase savings for seniors

August 6, 2024

What is the low-income subsidy program and how is it changing?

July 31, 2024

Three things to know about the United Nations’ new HIV/AIDS report

July 31, 2024

Case study: How seniors could face access disruptions because of the IRA’s price setting provisions

July 22, 2024

PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm

July 3, 2024

The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026

June 25, 2024

ICYMI: Misaligned policies undermine patient access

June 6, 2024

IRA is already negatively impacting access to medicines in Part D

April 25, 2024

New study finds insurers and PBMs increasing access restrictions in Medicare Part D

April 16, 2024

New analysis: Flawed assessments of a medicine’s value jeopardize patient access

April 11, 2024

3 Takeaways from POLITICO’s Health Care Summit

April 3, 2024

Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients

February 7, 2024

As the administration continues to falsely claim Medicare “negotiation,” keep these points in mind

February 1, 2024

New analysis of patient access restrictions in the United Kingdom

November 21, 2023

ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference

November 6, 2023

ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs

September 28, 2023

IRA threatens seniors’ access to robust treatment options

September 26, 2023

Medicare Prescription Payment Plan will benefit patients if implemented correctly

September 21, 2023

Correcting the record: IRA’s government price setting provisions are unconstitutional

September 8, 2023

IRA changes to Part D risk access to medicines

August 24, 2023

With the first list of medicines out, let’s not forget why government price setting is bad policy

August 22, 2023

One year later IRAs unintended consequences are becoming reality

August 16, 2023

AARP’s latest misleading report

August 11, 2023

Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation

July 26, 2023

Four things for CMS to keep in mind as they implement changes to Part D

June 7, 2023

CMS guidance on IRA price setting process doubles down on bad policy

April 14, 2023

A guide to MedPAC’s Part B vote today

April 13, 2023

MedPAC proposal threatens access to medicines in Part B

April 6, 2023

States can support access to medicine as COVID-19 Public Health Emergency ends

April 5, 2023

CMS coverage policy is detrimental to Alzheimer’s patients

April 4, 2023

How Part B’s ASP system helps control costs for the government and seniors

March 30, 2023

Medicare Part B spending in four points

March 28, 2023

Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines

January 31, 2023

In their own words: Insured Americans support policy reforms that address access and affordability concerns

December 14, 2022

Medicare Part D open enrollment and what recent changes mean for beneficiaries

November 17, 2022

Many seniors are paying more for Part D medicines than their insurer

October 18, 2022

Biosimilar uptake is increasing and so are health savings

October 17, 2022

Busting 3 Myths About Copay Coupons

October 5, 2022

CMS coverage policies restrict patient access to important treatment options for Alzheimer’s disease

September 1, 2022

Myth vs. Fact: The Senate’s latest price setting proposal

August 5, 2022

The Senate’s latest price setting proposal will undermine U.S. economic growth

August 3, 2022

Celebrating Medicare’s 57th anniversary

August 2, 2022

The Senate’s latest price setting proposal will undermine: Our health care system

July 28, 2022

The Senate’s latest price setting proposal will undermine: Patient access to medicines

July 26, 2022

New research shows competition driven by biosimilars helps control costs in Part B

July 19, 2022

Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients

July 12, 2022

CMS coverage decision restricts access to treatments for Alzheimer’s disease

June 22, 2022

Report finds PBMs are increasingly restricting patient access to medicines

May 25, 2022

Annual projections from NHE compared to actual health care spending

May 5, 2022

Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities

April 27, 2022

Part D 101: Three charts show how the program provides comprehensive prescription drug coverage

April 26, 2022

Government price setting leaves behind families counting on new medicines

February 23, 2022

Part B 101: Three charts show the program helps control costs for health care system and enrollees

February 18, 2022

PhRMA submits comments urging CMS to withdraw coverage proposal

February 11, 2022

Government price setting won’t stop insurers from shifting costs to patients

February 2, 2022

Research and development continues long after a medicine is initially approved

February 1, 2022

It’s a new year, but sadly Congress is still pursuing flawed price setting policies

January 25, 2022

Post-approval research save lives. Why is Congress trying disincentivize it?

December 17, 2021

A price control by any other name would still put patients at risk and threaten innovation

December 9, 2021

Making medicines more affordable: Making insurance work like insurance

December 8, 2021

3 things to know about the importance of post-approval research and development

December 6, 2021

Guest post: Congress should not put future innovation at risk

November 29, 2021

What is missing in the current drug pricing plan

November 23, 2021

ICYMI: PhRMA CEO speaks at STAT Summit about government price setting

November 19, 2021

Three things to know about so-called Medicare negotiation polling

November 18, 2021

In the current health care debate, Congress has lost sight of what matters to U.S. voters

November 15, 2021

Making medicines more affordable: Modernizing Medicare

November 11, 2021

What they are saying: Government price setting for medicines is not the answer

November 4, 2021

Four things to know from IQVIAs latest report

October 29, 2021

CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018

October 19, 2021

ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development

October 18, 2021

New poll shows Americans reject Medicare negotiation once they learn more about the policy

October 15, 2021

What is Kaiser Family Foundation up to?

October 12, 2021

Industry leaders discuss the impact of the drug pricing debate

September 23, 2021

Five reasons tying VA prices to Medicare Part D misses the mark

September 22, 2021

America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach

September 15, 2021

Recent polling misrepresents public support for Medicare “negotiation”

August 31, 2021

What they’re saying: Patient advocates want to protect Medicare from government interference

August 24, 2021

Myth vs. fact: Polling and Medicare “negotiation”

August 12, 2021

ICYMI: Event spotlights how we can make Medicare work better for patients

August 4, 2021

Celebrating Medicare’s 56th anniversary

July 30, 2021

Government “negotiation” could have devastating consequences for Medicare enrollees

July 23, 2021

Protecting Medicare from government interference

July 21, 2021

Data shows voters strongly support protecting access to their medicines

July 15, 2021

Medicare “negotiation” proposals threaten Americans’ access to medicines

June 30, 2021

The ABCs (and Ds) of Medicare

May 13, 2021

H.R. 3 threatens access to medicines, future innovation and American jobs

May 4, 2021

ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy

March 11, 2021

Getting the 340B program back on track in 2021

March 10, 2021

Key excerpts: PhRMA submits comments to keep the six protected classes protected

February 19, 2021

Action needed to preserve the six protected classes

February 3, 2021

End of year Part D reading List

December 18, 2020

New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England

December 10, 2020

No matter how you look at it, the Most Favored Nation rule is bad policy

December 1, 2020

Final rebate rule represents right way to change Medicare

December 1, 2020

Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R&D

November 16, 2020

Open Enrollment: How to find a Medicare plan that meets your needs

October 14, 2020

Three reasons why repealing the Part D non-interference clause is a bad idea

October 1, 2020

Growth in innovative, value-based contracts holds promise for the health system and for patients

September 24, 2020

Innovative contracts drive access for patients and value for the system

September 9, 2020

Supporting access to vaccines for Part D beneficiaries

August 12, 2020

ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19

August 4, 2020

Executive order threatens R&D when we need it most to fight COVID-19

July 30, 2020

Medicare’s 55th anniversary: Celebrating the success of Part D

July 30, 2020

PhRMA submits comments to CMS on policy changes for in-home care under Part B during COVID-19

May 6, 2020

The continued imperative to protect U.S. innovation worldwide

April 29, 2020

ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements

April 20, 2020

PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs

March 3, 2020

Addressing barriers that inhibit value-based contracts

February 21, 2020

Three reasons the Administration should abandon its International Pricing Index proposal

January 31, 2020

New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

November 4, 2019

Event tomorrow: Maintaining America’s leadership in access and innovation

October 16, 2019

Pelosi’s radical plan would leave Alzheimer’s patients behind

October 16, 2019

What they are saying: Broad opposition to Pelosi’s radical drug pricing plan

October 10, 2019

Four reasons why the radical Pelosi Plan is the wrong approach

September 24, 2019

Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important

September 4, 2019

Three reasons the Senate Finance package is the wrong approach for patients

August 26, 2019

New analysis: Government intervention in Part B threatens patient access to medicines

August 19, 2019

Setting the record straight on international reference pricing

July 16, 2019

No matter how you structure it, government arbitration is wrong for Medicare drug coverage

June 27, 2019

What you should know: Government arbitration is the wrong way to change Medicare

June 10, 2019

By the numbers: A look at the Part B International Pricing Index Model

June 6, 2019

How the rebate rule would help reduce patients’ out-of-pocket costs

June 3, 2019

Ask About Adherence: Improving adherence among osteoporosis patients could save up to $6.52 billion

May 29, 2019

Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence

May 15, 2019

4 Things to know about the IQVIA “Medicine Use and Spending” report

May 9, 2019

Event tomorrow: Improving access and affordability for America’s seniors

May 7, 2019

Fact Check: How the Part B International Pricing Index Model replaces market competition with government-set prices

May 3, 2019

Six policy solutions to help patients afford their insulin

April 9, 2019

PhRMA comments on OIG proposed rule to reform the rebate system

April 8, 2019

340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings

April 5, 2019

OIG proposed rule could help strengthen the Part D market

March 28, 2019

Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer

March 25, 2019

Bipartisan lawmakers urge Administration to rethink proposed changes to six protected classes policy

March 22, 2019

New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid

March 20, 2019

Changes to the six protected class policy are the wrong prescription for Medicare and HIV patients

March 15, 2019

Special 301 submission calls for a level playing field for American innovators

March 13, 2019

New analysis finds Average Sales Price system has led to significant cost savings for Medicare and seniors

March 7, 2019

New “Prescription for Medicare” campaign focuses on impacts of wrong and right solutions for Medicare

March 6, 2019

New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis

February 14, 2019

In survey, PhRMA member companies highlight impact of IPI on R&D

February 5, 2019

PhRMA comments to administration on Medicare Part D proposed rule

January 25, 2019

New research shows changes to the six protected classes would harm most vulnerable patients and are unnecessary

January 24, 2019

Keep the Six Protected Classes, protected

January 22, 2019

ICYMI: New study reinforces dangers of proposed IPI model

January 15, 2019

PhRMA comments to administration on International Pricing Index Model

January 3, 2019

10 things you should know about medicine spending and costs

January 2, 2019

ICYMI: WSJ and NYT highlight concerns with Part B International Pricing Index Model

December 19, 2018

Groups sound the alarm on administration’s new Part B proposal

November 14, 2018

4 things you need to know about the administration’s latest Part B proposal

November 5, 2018

PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation

November 2, 2018

PhRMA comments in response to request for information on competitive bidding program in Medicare Part B

September 25, 2018

What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?

September 13, 2018

Fact Check Friday: Getting the facts straight about negotiation in Medicare Part B

August 24, 2018

How much do you know about Medicare Part B?

July 31, 2018

ICER’s budget impact threshold: Sounding a false alarm on affordability and access

July 24, 2018

PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs

July 16, 2018

Event next week: Supporting the next generation of lifesaving medicines

July 12, 2018

Pass-through rebates do not violate non-interference clause but they do increase savings for seniors

July 2, 2018

Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge

June 28, 2018

Medicare Part D cliff ahead

June 21, 2018

Part D cliff looms for seniors, as program stability could be in jeopardy

June 18, 2018

New analysis shows that more medicines worldwide are available to U.S. patients

June 5, 2018